CRISPR Therapeutics CRSP

HealthcareMarket cap $5B7 connections

CRISPR Therapeutics (with Vertex) got the first CRISPR gene editing therapy approved - Casgevy, which functionally cures sickle cell disease. This is one of the most significant medical milestones in history. CRISPR's pipeline targets beta-thalassemia, cancer immunotherapy, and type 1 diabetes.

Open CRISPR Therapeutics's Company Hub Simulate a merger Supply chain See it on the map

Suppliers 1

Companies that sell to CRISPR Therapeutics

IlluminaHealthcare · $41BIllumina sequencing for CRISPR gene validation

Partners 5

Strategic partnerships, joint products and alliances

Vertex PharmaHealthcare · $133BCRISPR Therapeutics co-developer with Vertex
Beam TherapeuticsHealthcare · $3BCompeting next-gen gene editing modalities
Sarepta TherapeuticsHealthcare · $2BCompeting DMD gene therapy approaches
Intellia TherapeuticsHealthcare · $2BIntellia and CRISPR Therapeutics both in-vivo CRISPR
Editas MedicineHealthcare · $400MEditas and CRISPR Therapeutics competing CRISPR IP

Competitors 1

Companies it competes with

ModernaHealthcare · $79BGene therapy market

Other Healthcare companies

Eli Lilly Johnson & Johnson AbbVie Novo Nordisk Merck UnitedHealth Thermo Fisher AstraZeneca Amgen Novartis

Embed this on your site

Show CRISPR Therapeutics's network in an article or report - it updates as our data does.

<iframe src="https://vexmap.com/embed.html?co=CRSP" width="600" height="420" style="border:0;border-radius:12px;max-width:100%" title="CRISPR Therapeutics on VexMap" loading="lazy"></iframe>

Preview

Relationships are compiled by VexMap from company filings, announcements and reporting, and last reviewed September 2026. Spotted something wrong? Tell us. Not investment advice.